Status
Conditions
About
Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%. There is increasing evidence that sex-specific effects may lead to different outcomes of vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2 spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of immune response including age, gender and biological factors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
anti-SARS-CoV-2 serological test after vaccination
having already given their consent for their biological resources to be:
Exclusion criteria
Loading...
Central trial contact
Saïd CHAYER, PhD, HDR; Samira FAFI-KREMER, PharmD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal